AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

On Wednesday, May 8, AcelRx reported its financial results for Q1 2019 and gave updates on the Dsuvia commercialization process.

After Years Of Development, AcelRx's Dsuvia Has Finally Generated Revenue

The pharma announced first-quarter 2019 operating results.

Here's Why AcelRX Pharmaceuticals Fell as Much as 14% Today

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2019 Results - Earnings Call Transcript

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know

Bristol-Myers

Teladoc

They could be big winners for patient investors.

Three Stocks Peter Lynch Would Love: ACRX, BMY & TDOC

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?

On Thursday, March 7, AcelRx reported its 2018 financial results, presenting a strong picture overall.

AcelRx Reports Progress On Commercialization Of Dsuvia

Does AcelRx Pharmaceuticals (ACRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)

News for AcelRx Pharmaceuticals Stock (ACRX)